Orthocell is an Australian regenerative medicine company dedicated to restoring mobility and regenerating soft tissue. Founded in 2006, Orthocell provides new approaches to the regeneration of tendon, cartilage and the repair of soft tissue injuries.
To date the company has successfully developed and commenced commercialisation of two autologous (using a patient’s own cells) cell therapies for the treatment of damaged and degenerated tendons (Ortho-ATI®) as well as damaged and degenerated cartilage (Ortho-ACI®). Orthocell has also developed, and is readying for registration, a collagen scaffold product (CelGro®) for the repair and reconstruction of soft tissue injuries such as tendon tears, hernias and tympanic membrane (ear drum) reconstructions.
Orthocell is led by an experienced Board and management team, which have been responsible for the rapid development of the business. They have a successful track record of developing, protecting and commercialising novel scientific products and processes.
Orthocell’s Ortho-ATI® therapy is the first autologous cell therapy for tendon and ligament repair and regeneration licensed by a regulatory authority in the major markets of Australia, New Zealand, the USA, Europe, China and Japan. Ortho-ATI® clinical trials and case studies have demonstrated significant pain reduction and functional improvement in a range of different tendons including, gluteal and Extensor Carpi Radialis Brevis (ECRB) (tennis elbow) tendons. Clinical data at up to three years post intervention continues to demonstrate significant improvement in pain relief and function improvement.
Early commercialisation success
Orthocell has already secured approval to manufacture and market the Ortho-ATI® and Ortho-ACI® products in Australia and have treated more than 300 patients with each therapy to date. Awareness and support for the therapies continues to grow in Australia.
Promising new product and opportunity
Orthocell’s CelGro® collagen scaffold product is a promising new platform technology that provides the opportunity to enter the orthopaedic and general surgical markets for collagen scaffolds. CelGro® has many advantages over existing marketed naturally derived and synthetic scaffolds.